JP2016501013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501013A5 JP2016501013A5 JP2015541144A JP2015541144A JP2016501013A5 JP 2016501013 A5 JP2016501013 A5 JP 2016501013A5 JP 2015541144 A JP2015541144 A JP 2015541144A JP 2015541144 A JP2015541144 A JP 2015541144A JP 2016501013 A5 JP2016501013 A5 JP 2016501013A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- vitro
- cell activator
- γδt
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940126530 T cell activator Drugs 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000006052 T cell proliferation Effects 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- YKAYCWPQDPILSA-UHFFFAOYSA-N bromohydrin pyrophosphate Chemical compound BrCC(O)(C)CCOP(O)(=O)OP(O)(O)=O YKAYCWPQDPILSA-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306385.1 | 2012-11-08 | ||
| EP12306385 | 2012-11-08 | ||
| PCT/EP2013/073328 WO2014072446A1 (en) | 2012-11-08 | 2013-11-08 | Method for inducing il-2-free proliferation of gamma delta t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016501013A JP2016501013A (ja) | 2016-01-18 |
| JP2016501013A5 true JP2016501013A5 (enExample) | 2016-12-28 |
Family
ID=47189860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015541144A Pending JP2016501013A (ja) | 2012-11-08 | 2013-11-08 | γδＴ細胞の無ＩＬ−２増殖を誘導するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150259645A1 (enExample) |
| EP (1) | EP2916858A1 (enExample) |
| JP (1) | JP2016501013A (enExample) |
| WO (1) | WO2014072446A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201703767XA (en) | 2014-11-10 | 2017-06-29 | Genentech Inc | Anti-interleukin-33 antibodies and uses thereof |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| DK3220926T3 (da) | 2014-11-17 | 2025-03-24 | Adicet Therapeutics Inc | Konstruerede gamma-delta-t-celler |
| US20170360907A1 (en) | 2014-12-04 | 2017-12-21 | The University Of North Carolina At Chapel Hill | Compositions and methods for preventing and treating graft versus host disease |
| CA3023993A1 (en) | 2016-05-12 | 2017-11-16 | Adicet Bio Inc. | Methods for selective expansion of .gamma..delta. t-cell populations and compositions thereof |
| WO2018022575A1 (en) * | 2016-07-26 | 2018-02-01 | University Of Virginia Patent Foundation | Compositions and methods for treating clostridium difficile infection |
| CN108310367A (zh) * | 2017-01-18 | 2018-07-24 | 复旦大学 | 白介素33（il-33）在制备抗乙型肝炎病毒制剂中的用途 |
| US12161669B2 (en) * | 2017-05-18 | 2024-12-10 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| CA3082818A1 (en) | 2017-11-15 | 2019-05-23 | Adicet Bio Inc. | Methods for selective expansion of .delta.3 .gamma..delta. t-cell populations and compositions thereof |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN112930187A (zh) * | 2018-09-27 | 2021-06-08 | 弗斯弗加姆股份有限公司 | 用于同种异体γ/δ-T细胞的扩增和使用的方法和组合物 |
| CN109517793B (zh) * | 2018-11-30 | 2022-05-10 | 广州长峰生物技术有限公司 | 一种NK细胞和γδT细胞共培养的建立方法 |
| AU2019394877A1 (en) * | 2018-12-03 | 2021-06-17 | Adicet Therapeutics, Inc. | Methods for selective in vivo expansion of gamma delta T-cell populations and compositions thereof |
| TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素－３３抗體及其用途 |
| WO2023081802A2 (en) * | 2021-11-04 | 2023-05-11 | Memorial Sloan Kettering Cancer Center | Il33 proteins and methods of use thereof |
| WO2023132926A2 (en) * | 2022-01-04 | 2023-07-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compositions and methods for treating cancer |
| JPWO2023176896A1 (enExample) * | 2022-03-18 | 2023-09-21 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2782721B1 (fr) * | 1998-09-01 | 2000-11-03 | Inst Nat Sante Rech Med | Nouveaux composes phosphohalohydrines, procede de fabrication et applications |
| EP1426052B1 (en) * | 2002-12-02 | 2009-09-02 | Innate Pharma | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| WO2005077411A2 (en) * | 2004-02-10 | 2005-08-25 | Innate Pharma | Composition and method for the treatment of carcinoma |
| ITRM20070437A1 (it) * | 2007-08-10 | 2009-02-11 | Istituto Naz Per Le Malattie I | Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi |
| JP2010004853A (ja) * | 2008-06-30 | 2010-01-14 | Japan Health Science Foundation | 制御性ｔ細胞の製造方法 |
-
2013
- 2013-11-08 WO PCT/EP2013/073328 patent/WO2014072446A1/en not_active Ceased
- 2013-11-08 EP EP13791776.1A patent/EP2916858A1/en not_active Withdrawn
- 2013-11-08 JP JP2015541144A patent/JP2016501013A/ja active Pending
- 2013-11-08 US US14/440,921 patent/US20150259645A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501013A5 (enExample) | ||
| JP2017524031A5 (enExample) | ||
| WO2016070166A3 (en) | Messenger una molecules and uses thereof | |
| HK1203489A1 (en) | Purinone compounds as kinase inhibitors | |
| EA201401281A1 (ru) | D-аминокислотные химические соединения для лечения заболеваний печени | |
| JP2018512047A5 (enExample) | ||
| WO2015048689A8 (en) | Inhibitors of bruton's tyrosine kinase | |
| MX380555B (es) | Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| BR112014018524A2 (pt) | derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits | |
| MX2009006786A (es) | Composiciones y metodos para el tratamiento de infecciones y tumores. | |
| NZ609201A (en) | Means and methods for treating dlbcl | |
| CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| WO2015035136A8 (en) | Delivery system for functional nucleases | |
| BR112015022625A8 (pt) | microarranjo para entrega de agente terapêutico e métodos de utilização | |
| BR112015014751A2 (pt) | anticorpos anti-tau humanos | |
| MD20140035A2 (ro) | Metodă de tratament al hepatitei virale C | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| EP2743266A4 (en) | PROTEIN KINASE INHIBITORS (VARIANTS), THEIR USE FOR THE TREATMENT OF ONCOLOGICAL DISEASES AND PHARMACEUTICAL COMPOSITION BASED THEREFROM | |
| WO2018005521A3 (en) | Cell culture chambers and methods of use thereof | |
| JP2012515213A5 (enExample) | ||
| EP3826624A4 (en) | USE OF ANTI-CD2 ANTIBODY (ADC) DRUG CONJUGATE IN ALLOGENIC CELL THERAPY | |
| CL2020001358A1 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
| IL222343B (en) | Compositions comprising allogeneic th1 cells and inf-gamma for treating cancer or infectious diseases | |
| EA032977B1 (ru) | Генетически стабильный онколитический рнк вирус, способ его производства и применения |